Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 4,152 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total value of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $2.46 during midday trading on Thursday, reaching $66.28. 30,711,275 shares of the company traded hands, compared to its average volume of 15,817,041. Hims & Hers Health, Inc. has a twelve month low of $9.22 and a twelve month high of $72.98. The firm has a market capitalization of $14.48 billion, a price-to-earnings ratio of 150.64 and a beta of 1.35. The company has a fifty day moving average price of $33.94 and a 200 day moving average price of $25.19.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in the business. SlateStone Wealth LLC raised its stake in Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after acquiring an additional 628 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the last quarter. Finally, Harbour Investments Inc. grew its holdings in shares of Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HIMS. BTIG Research initiated coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Needham & Company LLC raised their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the company from $24.00 to $25.00 in a report on Friday, January 10th. Finally, Bank of America raised their price objective on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.